|
Robert A. Fildes Ph.D. has been a director of the Company since 1991. Since January 1998 Dr. Fildes has served as President of SB2 Inc. a privately held company which licenses antibody technology. From June to December 1998 Dr. Fildes served as Chief Executive Officer of Atlantic Pharmaceuticals a publicly held company in the field of biotechnology. From 1993 until August 1997 Dr. Fildes was the Chairman and Chief Executive Officer of Scotgen Biopharmaceuticals Inc. a privately held company in the field of human monoclonal antibody technology. Scotgen Biopharmaceuticals filed for Chapter 7 bankruptcy protection under the federal bankruptcy laws in August of 1997. From 1990 to 1993 Dr. Fildes was an independent consultant in the biopharmaceutical industry. He was the President and Chief Executive Officer of Cetus Corporation a publicly held biotechnology company from 1982 to 1990. From 1980 to 1982 Dr. Fildes was the President of Biogen Inc. a publicly held biopharmaceutical company and from 1975 to 1980 he was the Vice President of Operations for the Industrial Division of Bristol-Myers Squibb Company. Dr. Fildes is currently a director of Cytovax Biotechnologies Inc. a publicly held company that develops and commercializes vaccines and therapeutic products for the prevention and treatment of infectious diseases. Dr. Fildes holds a D.C.C. degree in Microbial Biochemistry and a Ph.D. in Biochemical Genetics from the University of London. | 